Failure to Thrive in Infants with Prader-Willi Syndrome and Long-Term Effects of Growth Hormone (GH) Treatment on Failure to Thrive (FTT)
Authors' conclusion
Twenty-nine percent of infants had FTT at 1 month, 20% at 3 months, and 16% at 6 months. Twelve percent had FTT at the start of GH treatment. Children with FTT at GH start showed greatest LBM improvement during GH treatment, resulting in a similar LBM after 5 years of GH treatment as those without FTT at GH start.
Study context
- Population
- Infants and children with Prader-Willi syndrome (PWS) treated with GH 1.0 mg/m²/day (∼0.035 mg/kg/day); body composition by DXA54 infants for FTT prevalence
- Participants
- 166 participants
- Exposure
- Children with vs without FTT at GH start
- FTTGH startn = 20
- Outcome
- Percentage of infants with FTT (weight-for-length <−2 SDS) from birth to age 6 months; 5-year GH effects on body composition in infants with or without FTT at GH start
- Follow-up
- Birth to 6 months; 5 years of GH
Main finding
As reported in the abstract
FTT at 1 month
29%
FTT at 3 months
20%
FTT at 6 months
16%
FTT at GH start (median age 1.03 [IQR 0.45, 1.89] years)
12%
20/166
Observational data: associations, not effects.
Original publication
Failure to Thrive in Infants with Prader-Willi Syndrome and Long-Term Effects of GH Treatment on FTT. Horm Res Paediatr. Published 24 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →